Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia

Simple item page
dc.contributor.authorVan Rensburg, S. J.
dc.contributor.authorSmuts, C. M.
dc.contributor.authorHon, D.
dc.contributor.authorKidd, M.
dc.contributor.authorVan Der Merwe, S.
dc.contributor.authorMyburgh, C.
dc.contributor.authorOosthuizen, P.
dc.contributor.authorEmsley, R.
dc.date.accessioned2011-05-15T16:17:22Z
dc.date.available2011-05-15T16:17:22Z
dc.date.issued2009
dc.description.abstractIn a previously reported double-blind, placebo-controlled trial of eicosapentaenoic acid (EPA) as supplemental treatment in 40 patients with schizophrenia, we found significant improvement in symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) compared to placebo (Emsley et al. 2002). Here we report changes in fatty acid composition of erythrocyte membranes in the same sample (n∈=∈16 in each group). After 12 weeks of receiving EPA, levels of several saturated and mono-unsaturated fatty acids decreased significantly while levels of n-3 fatty acids increased significantly compared to the placebo group. Increases of n-3 and n-6 fatty acids in the erythrocyte membranes were greater in subjects who improved more than 20% on overall symptoms. Changes in fatty acids correlated significantly with improvement in PANSS sub-scale scores, more so in females than in males. Docosahexaenoic acid (DHA) (22:6n-3) levels increased less than expected, suggesting a possible defect in synthesis or incorporation of DHA into membranes in schizophrenia. Improvement in dyskinesia correlated significantly with an increase in alpha-linolenic acid (18:3n-3; p∈=∈0.03), and a decrease in 20:1n-9 (p∈=∈0.005). © 2009 Springer Science+Business Media, LLC.
dc.description.versionArticle
dc.identifier.citationMetabolic Brain Disease
dc.identifier.citation24
dc.identifier.citation4
dc.identifier.issn08857490
dc.identifier.other10.1007/s11011-009-9160-7
dc.identifier.urihttp://hdl.handle.net/10019.1/14189
dc.subjectdocosahexaenoic acid
dc.subjectfatty acid
dc.subjecticosapentaenoic acid
dc.subjectlinoleic acid
dc.subjectmonounsaturated fatty acid
dc.subjectomega 3 fatty acid
dc.subjectomega 6 fatty acid
dc.subjectplacebo
dc.subjectsaturated fatty acid
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectdiet supplementation
dc.subjectdouble blind procedure
dc.subjectdyskinesia
dc.subjecterythrocyte membrane
dc.subjectextrapyramidal symptom
dc.subjectfatty acid analysis
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectmental disease
dc.subjectPositive and Negative Syndrome Scale
dc.subjectrandomized controlled trial
dc.subjectschizophrenia
dc.subjectscoring system
dc.subjectsex difference
dc.subjectsingle blind procedure
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectalpha-Linolenic Acid
dc.subjectDietary Supplements
dc.subjectDisability Evaluation
dc.subjectDocosahexaenoic Acids
dc.subjectDyskinesias
dc.subjectEicosapentaenoic Acid
dc.subjectErythrocytes
dc.subjectFatty Acids
dc.subjectFatty Acids, Monounsaturated
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMembrane Lipids
dc.subjectMiddle Aged
dc.subjectNeuropsychological Tests
dc.subjectSchizophrenia
dc.subjectTreatment Outcome
dc.subjectUp-Regulation
dc.subjectYoung Adult
dc.titleChanges in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications